|
|
Article: Endovasc Concludes Studies at Washington Hospital and Texas Heart Institute; Endovasc and Texas Heart Agree to Second Year Contract.
- Article from:
- Business Wire
- Article date:
- March 17, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
MONTGOMERY, Texas--(BUSINESS WIRE)--March 17, 2004
Endovasc Inc. (OTCBB: EVSC), an early-stage drug development company that pioneers new cardiovascular and metabolic drug therapies, announced today the completion of porcine studies that examined a variety of delivery systems for Angiogenix(TM) performed by Dr. Ron Waksman and his team at Washington Hospital in Washington D.C. The study explored less invasive and less costly methods to deliver the drug to damaged areas of the heart rather than the catheter based delivery system used previously.
In a second study, in collaboration with Endovasc Inc., ...